Press

5 November 2026

Sentinal4D launches pilot programme with the Stevenage Bioscience Catalyst to advance treatment candidates

Sentinal4D is offering fully funded pilot projects with the Stevenage Bioscience Catalyst to strengthen the existing analysis pipelines of early-stage biotech companies

Fully funded pilot projects will provide access to Revvity’s advanced cellular imaging technology and Sentinal4D’s living biology models to get more insight from every experiment.

Stevenage, UK, 5 November 2026. Sentinal4D has launched a pilot programme in collaboration with the Stevenage Bioscience Catalyst (SBC) and with support from Hertfordshire Futures. The fully funded pilots provide early-stage biotech companies access to specialist imaging and Sentinal4D’s living biology models to help prioritise better assets sooner.

The programme combines Revvity’s newly installed Opera Phenix high-content imaging platform with Sentinal4D’s models to capture detailed images of cells and complex biological models, and analyse changes in cell shape, structure, and behaviour. This way, researchers can discover, develop, de-risk, and even design better treatment candidates with higher efficiency.

“Our ambition at SBC is to reduce the time and cost required for biotech companies to reach critical scientific milestones, generate the evidence needed to de-risk their programmes and attract investment, and ultimately accelerating the journey from scientific discovery to patients.

“For early-stage biotech companies, every experiment comes with a cost, and every delay can slow down the development of a potential new therapy. We want to change that by combining free access to shared infrastructure, cutting-edge technologies and AI-driven expertise.

“This collaboration with Sentinal4D, powered by Revvity’s technology, is an important step towards that vision.”

Marco Delise PhD, Director of Entrepreneurship and Business Development, Stevenage Bioscience Catalyst

Funded pilot projects and independent access

During the initial six-month pilot, Sentinal4D will manage the Opera Phenix platform and provide specialist imaging and AI analysis services to SBC companies. The equipment will also be available for independent use.

“Cells contain an extraordinary amount of information about how treatments work, but much of it remains hidden using conventional approaches.

“By combining high-content imaging with our models, we can uncover biological patterns that help researchers better understand drug activity, mechanisms of action and potential toxicity.

“Through this collaboration with SBC, we’re excited to make these capabilities accessible to innovative biotech companies and help accelerate the development of new therapies.”

Professor Chris Bakal, CEO and Co-founder, Sentinal4D
The Sentinal4D team beside a Sentinal4D banner at Stevenage Bioscience Catalyst
A Sentinal4D presentation to biotech companies
A demonstration of high-content imaging in the lab

Businesses interested can discover more and apply here.

Notes to editors

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst (SBC) is an independent, not-for-profit life sciences campus in Stevenage, Hertfordshire. SBC brings together scientists, entrepreneurs and life sciences companies and helps them advance their research and grow through access to shared laboratories, specialist equipment and business support. Since opening in 2012, SBC has hosted more than 120 companies. SBC companies have raised £4.5 billion.

About Sentinal4D

Sentinal4D is building proprietary AI models trained on the largest dataset of living biology, helping companies uncover patterns in cellular behaviour and understand not just which assets work, but why. The company is a spinout from The Institute of Cancer Research (ICR) and is supported by Twin Path Ventures.